Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
暂无分享,去创建一个
M. Peiris | S. Cheng | W. Wong | S. Chan | S. M. Chan | Y. Lau | D. Leung | J. S. Rosa Duque | M. K. L. Yu | Amy Suen Ka Yan | J. R. Rosa Duque
[1] D. Skowronski,et al. BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration , 2023, The Journal of infectious diseases.
[2] H. So,et al. Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong , 2023, Communications Medicine.
[3] H. So,et al. COVID-19 vaccines versus pediatric hospitalization , 2023, Cell Reports Medicine.
[4] R. Webby,et al. Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents , 2022, Signal transduction and targeted therapy.
[5] Toshio Saito,et al. Safety and immunogenicity of mRNA COVID‐19 vaccine in inpatients with muscular dystrophy , 2022, Muscle & nerve.
[6] T. Gonen,et al. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose , 2022, The New England journal of medicine.
[7] A. Okumura,et al. Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders , 2022, Frontiers in Immunology.
[8] M. Peiris,et al. Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity , 2022, Frontiers in Immunology.
[9] N. Pearce,et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period , 2022, Nature Communications.
[10] J. Lazarus,et al. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021 , 2022, Nature Communications.
[11] E. Lau,et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study , 2022, The Lancet Infectious Diseases.
[12] M. Peiris,et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents , 2022, Nature Communications.
[13] J. Chan,et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections , 2022, Emerging microbes & infections.
[14] R. Rojas-García,et al. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis , 2022, Neurology: Neuroimmunology & Neuroinflammation.
[15] Minal K. Patel,et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant , 2022, The Lancet Infectious Diseases.
[16] E. Undurraga,et al. Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile , 2022, Nature Medicine.
[17] R. Link-Gelles,et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. , 2022, JAMA.
[18] Manish M Patel,et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents , 2022, The New England journal of medicine.
[19] Mohammad Ali,et al. Parental COVID-19 vaccine hesitancy for children with neurodevelopmental disorders: a cross-sectional survey , 2022, Tropical Medicine and Health.
[20] B. Walker,et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals , 2022, Cell.
[21] P. Moss. The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.
[22] P. López-Jaramillo,et al. Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis , 2022, eClinicalMedicine.
[23] L. Poon,et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.
[24] A. Sette,et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant , 2022, Nature Medicine.
[25] W. Wong,et al. Adolescents’ attitudes to the COVID-19 vaccination , 2022, Vaccine.
[26] G. Wong,et al. Updated consensus statements on COVID-19 Vaccine Allergy Safety in Hong Kong , 2022, Asia Pacific allergy.
[27] D. Shay,et al. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021. , 2021, MMWR. Morbidity and mortality weekly report.
[28] E. Jassem,et al. Morbidity, Clinical Course and Vaccination against SARS-CoV-2 Virus in Patients with Duchenne Muscular Dystrophy: A Patient Reported Survey , 2021, International journal of environmental research and public health.
[29] T. Ndung’u,et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.
[30] M. Kraemer,et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.
[31] Heidi Ledford,et al. How COVID vaccines shaped 2021 in eight powerful charts , 2021, Nature.
[32] F. Briggs,et al. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis , 2021, Neurology: Neuroimmunology & Neuroinflammation.
[33] T. McDade,et al. mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease , 2021, Neuromuscular Disorders.
[34] C. Wiysonge,et al. Understanding COVID-19 vaccine hesitancy , 2021, Nature Medicine.
[35] C. Handberg,et al. Impact of the COVID-19 pandemic on biopsychosocial health and quality of life among Danish children and adults with neuromuscular diseases (NMD)—Patient reported outcomes from a national survey , 2021, PloS one.
[36] P. Narayanaswami,et al. Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders , 2021, Muscle & nerve.
[37] L. Poon,et al. Neutralizing antibody titres in SARS-CoV-2 infections , 2021, Nature communications.
[38] M. Rubio,et al. Neuromuscular Diseases Care in the Era of COVID-19 , 2020, Frontiers in Neurology.
[39] J. Peiris,et al. Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera , 2020, medRxiv.
[40] Malik Peiris,et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[41] C. Wiysonge,et al. Current tools available for investigating vaccine hesitancy: a scoping review protocol , 2019, BMJ Open.
[42] J. Orange,et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. , 2012, The Journal of allergy and clinical immunology.
[43] A. Verbeek,et al. The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. , 2015, Journal of neuromuscular diseases.